UroGen Pharma Ltd.

NasdaqGM:URGN Stock Report

Market Cap: US$487.4m

UroGen Pharma Balance Sheet Health

Financial Health criteria checks 4/6

UroGen Pharma has a total shareholder equity of $25.5M and total debt of $121.7M, which brings its debt-to-equity ratio to 477%. Its total assets and total liabilities are $301.9M and $276.4M respectively.

Key information

477.0%

Debt to equity ratio

US$121.71m

Debt

Interest coverage ration/a
CashUS$249.58m
EquityUS$25.52m
Total liabilitiesUS$276.43m
Total assetsUS$301.94m

Recent financial health updates

Recent updates

Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load?

Nov 18
Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load?

UroGen Pharma: There Is Some Potential Here

Aug 28

UroGen: Q3 NDA Opens Hefty Revenue Opportunity

Jun 17

UroGen Pharma Ltd.'s (NASDAQ:URGN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

Jun 14
UroGen Pharma Ltd.'s (NASDAQ:URGN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

Apr 09
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

UroGen: All Eyes On UGN-102

Mar 18

UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Mar 17
UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates

UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough

Jan 18
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough

UroGen gets FDA nod for extending duration of Jelmyto admixture

Sep 28

Financial Position Analysis

Short Term Liabilities: URGN's short term assets ($295.1M) exceed its short term liabilities ($32.8M).

Long Term Liabilities: URGN's short term assets ($295.1M) exceed its long term liabilities ($243.6M).


Debt to Equity History and Analysis

Debt Level: URGN has more cash than its total debt.

Reducing Debt: URGN's debt to equity ratio has increased from 0% to 477% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: URGN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if URGN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies